WO2023136486A1 - Procédé et dispositif de typage d'antigène leucocytaire humain - Google Patents

Procédé et dispositif de typage d'antigène leucocytaire humain Download PDF

Info

Publication number
WO2023136486A1
WO2023136486A1 PCT/KR2022/020521 KR2022020521W WO2023136486A1 WO 2023136486 A1 WO2023136486 A1 WO 2023136486A1 KR 2022020521 W KR2022020521 W KR 2022020521W WO 2023136486 A1 WO2023136486 A1 WO 2023136486A1
Authority
WO
WIPO (PCT)
Prior art keywords
hla
hla typing
tools
tool
determining
Prior art date
Application number
PCT/KR2022/020521
Other languages
English (en)
Korean (ko)
Inventor
송성재
서정한
임채열
Original Assignee
주식회사 네오젠티씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 네오젠티씨 filed Critical 주식회사 네오젠티씨
Publication of WO2023136486A1 publication Critical patent/WO2023136486A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio

Definitions

  • the present disclosure relates to genetic analysis, and more specifically to determining the type of human leukocyte antigen.
  • HLA Human Leukocyte Antigen
  • MHC Major Histocompatibility Complex
  • HLA a product of the MHC gene
  • HLA is the second most important antigen next to the ABO blood type in survival of the transplanted organ in solid organ transplantation.
  • HLA is known to play the most important role in transplantation success or failure in bone marrow transplantation. Therefore, recognizing the difference in HLA immunologically can be seen as the first step of the rejection action for the transplanted tissue.
  • HLA and antibodies play an important role in the occurrence of various side effects such as platelet transfusion refractory, febrile nonhemorrhagic transfusion side effects, acute lung injury, and graft-versus-host disease after transfusion.
  • HLA can be largely classified into Class I and Class II.
  • Class I is classified into HLA-A, HLA-B, and HLA-C, and is expressed in most nucleated cells and platelets, and antigen recognition when cytotoxic T cells recognize and remove virus-infected cells or tumor cells.
  • HLA-DR is essential for HLA Class II
  • HLA-DQ is essential for HLA Class II
  • HLA-DP is classified into HLA-DR, HLA-DQ, and HLA-DP, and is expressed in B cells, monocytes, dendritic cells, and activated T cells. and induces a humoral immune response, and is known to be essential when recognizing antigens expressed in antigen-presenting cells.
  • HLA is a gene that shows the largest polymorphism among genes possessed by humans, and there is a frequency difference between races and ethnic groups.
  • HLA typing for determining the exact HLA type is required in various fields such as organ transplantation, immunotherapy, disease-related research, paternity tests such as paternity, forensic use, and genetic research.
  • various HLA types have been analyzed based on PCR-SSP, PCR-SSOP, Polymerase Chain Reaction-Sequencing Based Typing (PCR-SBT) technologies and Next Generation Sequencing (NGS) methods. Methods have been suggested.
  • the NGS method is based on exon 2, 3, and 4 for Class I (HLA-A, -B, -C) and exon 2 (or exon 2) for Class II (DRB1, DQB1, DPB1), which has been mainly performed in the PCR-SBT test method. , 3), more genes and more exons can be analyzed at the same time, which eliminates the need for additional primers and group PCR, which have been trying to reduce the ambiguity rate. It has the advantage of pooling multiple target genes or multiple samples at once.
  • the prediction accuracy is relatively high for commonly found HLA alleles, but the accuracy is low for infrequent alleles. Therefore, it is not only necessary to build a highly reliable method for more accurately predicting the HLA type, but also, depending on the individual, accurate typing is required by additionally performing the PCR-SBT test method even after NGS.
  • neoantigens generated from tumors caused by somatic mutations has been developed.
  • a tumor vaccine can be produced from it, or T cells with a T cell receptor (TCR) capable of attacking tumors in response to the neoantigen are selected, and the selected T cells are selected.
  • TCR T cell receptor
  • a therapeutic agent may be prepared by culturing cells in vitro or by manufacturing a TCR engineered T cell (TCR engineered T cell) having a T cell receptor engineered.
  • TCR engineered T cell TCR engineered T cell having a T cell receptor engineered.
  • the mutant protein may be combined with HLA and presented as a neoantigen according to the type of HLA of each patient.
  • HLA human leukocyte antigen
  • a method for determining a type of Human Leukocyte Antigen (HLA) performed by a computing device may include obtaining a result of performing nucleotide sequence analysis on DNA or RNA obtained from a biological sample derived from a subject; and determining the HLA type of the biological sample by using a plurality of HLA typing tools that take the result of the sequencing as an input.
  • HLA Human Leukocyte Antigen
  • the step of determining the HLA type may include, based on HLA type candidates included in calls obtained from the plurality of HLA typing tools and complementary scores between the plurality of HLA typing tools, the It may include determining the HLA type for the biological sample.
  • the determining of the HLA type may include determining the number of tools presenting calls among the plurality of typing tools; and determining the HLA type based on the determined number of tools.
  • the determining of the HLA type may include determining the number of tools presenting calls among the plurality of typing tools; Calculating a degree of agreement between HLA type candidates included in the presented calls; and determining the HLA type based on the determined number of tools and the calculated degree of agreement.
  • the determining of the HLA type may include calculating a complementary score between any two typing tools among the plurality of HLA typing tools; and determining the HLA type of the biological sample based on the complementary score.
  • the complementarity score may include a value quantitatively indicating the possibility that any two HLA typing tools among the plurality of HLA typing tools can be used together to determine the HLA type.
  • the complementary score may include a value quantitatively indicating the accuracy of the determined HLA type when any two HLA typing tools among the plurality of HLA typing tools are used together.
  • the complementary score is a correction value to be applied to HLA type candidates included in calls obtained from two HLA typing tools when any two of the plurality of HLA typing tools are used together. It may include a value that quantitatively represents.
  • a complementary score between a first HLA typing tool and a second HLA typing tool among the plurality of HLA typing tools is a result of a first call obtained from the first HLA typing tool for the biological sample.
  • a value quantitatively indicative of the accuracy of the result for the second call obtained from the second HLA typing tool for the biological sample is a value quantitatively indicative of the accuracy of the result for the second call obtained from the second HLA typing tool for the biological sample.
  • the complementary score between a first HLA typing tool and a second HLA typing tool among the plurality of HLA typing tools is the determined score when the first HLA typing tool is used together with the second HLA typing tool.
  • the accuracy value for the HLA type may include a value quantitatively representing a result of comparison with a predetermined first accuracy value for the first HLA typing tool.
  • the determining of the HLA type may include determining whether to combine a first call obtained from a first HLA typing tool and a second call obtained from a second HLA typing tool among the plurality of HLA typing tools. determining based on a first complementary score between the first HLA typing tool and the second HLA typing tool; and determining the HLA type based on a decision on whether to combine the first call and the second call.
  • the determining of the HLA type may include whether to combine a first call obtained from a first HLA typing tool and a second call obtained from a second HLA typing tool among the plurality of HLA typing tools, to a first complementary score between the first HLA typing tool and the second HLA typing tool, a first predetermined accuracy value for the first HLA typing tool and a second predetermined accuracy value for the second HLA typing tool determining based on; and determining the HLA type based on a determination as to whether to combine the first call and the second call.
  • the determining of the HLA type may include determining a correction value to be applied to a first call obtained from a first HLA typing tool and a second call obtained from a second HLA typing tool among the plurality of HLA typing tools. determining based on a first complementary score between the first HLA typing tool and the second HLA typing tool; and determining the HLA type based on the correction value.
  • the determining of the HLA type comprises determining accuracy of the HLA type when using the plurality of HLA typing tools based at least in part on a complementary score associated with the plurality of HLA typing tools. It may include predicting.
  • the complementary score is determined by determining whether a first result from a first HLA typing tool among the plurality of HLA typing tools does not match an actual result, and a second result from a second HLA typing tool being the actual result.
  • a first sub-score indicating the case of coincidence with; a second sub-score indicating a case in which a first result from a first HLA typing tool matches an actual result when a second result from a second HLA typing tool among the plurality of HLA typing tools does not match an actual result; a first predetermined accuracy value for the first HLA typing tool; and a predetermined second accuracy value for the second HLA typing tool.
  • the method may further include determining a degree of similarity between algorithms included in the plurality of HLA typing tools based on the complementarity score.
  • a computer program stored in a computer readable storage medium when executed by one or more processors, may perform a method for determining the type of Human Leukocyte Antigen (HLA).
  • the method includes: acquiring a result of performing nucleotide sequence analysis on DNA or RNA obtained from a biological sample derived from a subject; and determining the HLA type of the biological sample by using a plurality of HLA typing tools that take the sequencing result as an input.
  • a computing device for determining the type of Human Leukocyte Antigen (HLA) is disclosed.
  • the computing device may include a memory; and a processor, wherein the processor: obtains a result of performing nucleotide sequence analysis on DNA or RNA obtained from a biological sample derived from the subject;
  • the HLA type of the biological sample may be determined using a plurality of HLA typing tools that take the sequencing result as an input.
  • the method and apparatus according to one embodiment of the present disclosure are intended to more accurately and efficiently determine or predict the type of human leukocyte antigen (HLA).
  • HLA human leukocyte antigen
  • a method and apparatus may determine similarity between a plurality of tools for determining the type of human leukocyte antigen (HLA).
  • HLA human leukocyte antigen
  • FIG. 1 schematically illustrates a block configuration diagram of a computing device according to an embodiment of the present disclosure.
  • FIG. 2 illustrates an exemplary method for determining HLA type according to one embodiment of the present disclosure.
  • FIG. 3 illustrates an example algorithm for determining a complementarity score, according to one embodiment of the present disclosure.
  • FIG. 4 illustrates an exemplary algorithm for determining a complementarity score, according to one embodiment of the present disclosure.
  • FIG. 5 depicts an exemplary algorithm for determining a complementarity score according to one embodiment of the present disclosure.
  • FIG. 6 is a schematic diagram of a computing environment according to one embodiment of the present disclosure.
  • a component may be, but is not limited to, a procedure, processor, object, thread of execution, program, and/or computer running on a processor.
  • an application running on a computing device and a computing device may be components.
  • One or more components may reside within a processor and/or thread of execution.
  • a component can be localized within a single computer.
  • a component may be distributed between two or more computers. Also, these components can execute from various computer readable media having various data structures stored thereon.
  • Components may be connected, for example, via signals with one or more packets of data (e.g., data and/or signals from one component interacting with another component in a local system, distributed system) to other systems and over a network such as the Internet. data being transmitted) may communicate via local and/or remote processes.
  • packets of data e.g., data and/or signals from one component interacting with another component in a local system, distributed system
  • a network such as the Internet. data being transmitted
  • the term “or” is intended to mean an inclusive “or” rather than an exclusive “or”. That is, unless otherwise specified or clear from the context, “X employs A or B” is intended to mean one of the natural inclusive substitutions. That is, X uses A; X uses B; Or, if X uses both A and B, "X uses either A or B" may apply to either of these cases. Also, the term “and/or” as used herein should be understood to refer to and include all possible combinations of one or more of the listed related items.
  • Nth such as first, second, or third
  • first, second, or third are used to distinguish at least one entity.
  • entities represented as first and second may be the same as or different from each other.
  • sequencing may be performed by any type of technique capable of sequencing, for example, whole genome sequencing, whole exome base It may include, but is not limited to, whole exome sequencing or whole transcriptome sequencing.
  • a subject may refer to a subject or individual for determining an HLA type.
  • sample can be used without limitation as long as it is obtained from an individual or subject whose HLA type is to be determined, for example, cells or tissues obtained by biopsy, blood, whole blood, serum, plasma, saliva, It may be cerebrospinal fluid, various secretions, urine and/or feces, and the like.
  • the sample may be selected from the group consisting of blood, plasma, serum, saliva, nasal fluid, sputum, ascites, vaginal secretion and/or urine, and more preferably blood, plasma or serum.
  • the sample may be pretreated prior to use for detection or diagnosis.
  • pretreatment methods may include homogenization, filtration, distillation, extraction, concentration, inactivation of interfering components, and/or addition of reagents, and the like.
  • a biological sample may be tissue, cell, whole blood, and/or blood, but is not limited thereto.
  • HLA Human Leukocyte Antigen
  • MHC major histocompatibility complex
  • An HLA type in the present disclosure may include, for example, an HLA-A type, an HLA-B type, and/or an HLA-C type.
  • a plurality of tools for HLA typing are exemplarily disclosed.
  • Tools in the present disclosure may include algorithms for genetic analysis.
  • the tool may include an algorithm for HLA typing.
  • HLA typing methods and tools in the present disclosure may be used interchangeably with each other.
  • OptiType is an HLA genotype determination algorithm based on integer linear programming announced in 2014. It selects all major or minor HLA class I alleles and accurately predicts 4-digit HLA genotype from NGS data. .
  • OptiType is known to have problems in terms of accuracy and usability (see Szolek et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatic, Vol. 30 no. 23 2014, pages 3310-3316).
  • HLA-HD is a method that can accurately determine HLA alleles with 6-digit precision from NGS data published in Japan in 2017. For details, see Hum Mutat. 2017 Jul;38(7):788-797. doi: 10.1002/humu.23230. (Kawaguchi, Shuji, et al. Human mutation 38.7 (2017): 788-797.) can refer
  • PHLAT is a method designed for high-resolution (six-digit) typing of major class I and class II HLA genes using RNAseq or exome sequencing data as input.
  • RNAseq or exome sequencing data as input.
  • HLAscan is a method for performing read alignment on HLA sequences from the International ImMunoGeneTics Project/Human Leukocyte Antigen (IMGT/HLA) database.
  • IMGT/HLA International ImMunoGeneTics Project/Human Leukocyte Antigen
  • HLA*LA is a model that infers HLA types based on projecting linear alignment onto a variance graph, and is a method capable of accurately predicting HLA genotypes from whole-exome and whole-genome Illumina data. For details, see Dilthey, Alexander T., et al. "HLA* LA-HLA typing from linearly projected graph alignments.” Bioinformatics 35.21 (2019): 4394-4396.
  • Availability and/or accuracy of HLA typing results according to each of the above HLA typing methods may be different. Accordingly, a method for determining an optimal HLA type with higher accuracy is required.
  • FIG. 1 schematically illustrates a block configuration diagram of a computing device 100 according to one embodiment of the present disclosure.
  • Computing device 100 may include a processor 110 and a memory 130 .
  • the configuration of the computing device 100 shown in FIG. 1 is only a simplified example.
  • the computing device 100 may include other components for performing a computing environment of the computing device 100, and only some of the disclosed components may constitute the computing device 100.
  • the computing device 100 in the present disclosure may refer to a node constituting a system for implementing embodiments of the present disclosure.
  • the computing device 100 may refer to any type of user terminal or any type of server.
  • Components of the aforementioned computing device 100 are exemplary and some may be excluded or additional components may be included.
  • an output unit (not shown) and an input unit (not shown) may be included within its scope.
  • the computing device 100 in the present disclosure may perform technical features according to embodiments of the present disclosure to be described later.
  • the computing device 100 may determine the HLA type of the biological sample based at least in part on typing results from a plurality of HLA typing tools that take as input a result of performing sequencing of the biological sample. .
  • the processor 110 may include at least one core, and may include a central processing unit (CPU) or a general purpose graphics processing unit (GPGPU) of the computing device 100 . , a processor for data analysis and/or processing, such as a tensor processing unit (TPU).
  • the processor 110 reads the computer program stored in the memory 130 and, according to an embodiment of the present disclosure, typing results from a plurality of HLA typing tools that take as input a result of base sequence analysis on a biological sample.
  • the HLA type for the biological sample may be determined based, at least in part, on.
  • the processor 110 reads the computer program stored in the memory 130 and, according to an embodiment of the present disclosure, HLA type candidates included in calls obtained from a plurality of HLA typing tools and the plurality of HLAs An HLA type of the biological sample may be determined based on a complementary score between typing tools.
  • the processor 110 may perform an operation for learning a neural network.
  • the processor 110 is used for neural network learning, such as processing input data for learning in deep learning (DL), extracting features from input data, calculating errors, and updating neural network weights using backpropagation. calculations can be performed.
  • At least one of the CPU, GPGPU, and TPU of the processor 110 may process learning of the network function.
  • the CPU and GPGPU can process learning of network functions and data classification using network functions.
  • learning of a network function and data classification using a network function may be processed by using processors of a plurality of computing devices together.
  • a computer program executed in a computing device may be a CPU, GPGPU or TPU executable program.
  • the processor 110 may typically handle overall operations of the computing device 100 .
  • the processor 110 processes data, information, signals, etc. input or output through components included in the computing device 100 or drives an application program stored in a storage unit, thereby providing appropriate information or information to the user.
  • a function can be provided or processed.
  • memory 130 may store any type of information generated or determined by processor 110 and any type of information received by computing device 100 .
  • the memory 130 may be a storage medium that stores computer software that causes the processor 110 to perform operations according to embodiments of the present disclosure.
  • the memory 130 may refer to computer readable media for storing software codes necessary for performing embodiments of the present disclosure, data subject to execution of the codes, and results of execution of the codes.
  • the memory 130 may refer to any type of storage medium.
  • the memory 130 may be a flash memory type, a hard disk type ), multimedia card micro type, card type memory (eg SD or XD memory, etc.), RAM (Random Access Memory, RAM), SRAM (Static Random Access Memory), ROM (Read-Only memory, ROM), electrically erasable programmable read-only memory (EEPROM), programmable read-only memory (PROM), magnetic memory, magnetic disk, and optical disk.
  • the computing device 100 may operate in relation to a web storage that performs a storage function of the memory 130 on the Internet.
  • the description of the above memory is only an example, and the memory 130 used in the present disclosure is not limited to the above example.
  • the communication unit (not shown) in the present disclosure may be configured regardless of its communication mode, such as wired and wireless, and may be configured in various communication networks such as a personal area network (PAN) and a wide area network (WAN). can be configured.
  • the network unit 150 may operate based on the known World Wide Web (WWW), and a wireless transmission technology used for short-range communication such as Infrared Data Association (IrDA) or Bluetooth. can also be used.
  • WWW World Wide Web
  • IrDA Infrared Data Association
  • Bluetooth can also be used.
  • the computing device 100 in the present disclosure may include any type of user terminal and/or any type of server. Accordingly, embodiments of the present disclosure may be performed by a server and/or a user terminal.
  • a user terminal may include any type of terminal capable of interacting with a server or other computing device.
  • User terminals include, for example, mobile phones, smart phones, laptop computers, personal digital assistants (PDAs), slate PCs, tablet PCs, and ultrabooks.
  • PDAs personal digital assistants
  • slate PCs slate PCs
  • tablet PCs tablet PCs
  • ultrabooks can include
  • a server may include any type of computing system or computing device, such as, for example, microprocessors, mainframe computers, digital processors, portable devices and device controllers, and the like.
  • the server may refer to an entity that stores and manages nucleotide sequence information or gene information.
  • the server may include a storage unit (not shown) for storing nucleotide sequence information, gene information, and/or index information, and the storage unit may be included in the server or exist under the management of the server.
  • the storage unit may exist outside the server and may be implemented in a form capable of communicating with the server. In this case, the storage unit may be managed and controlled by another external server different from the server.
  • FIG. 2 illustrates an exemplary method for determining HLA type according to one embodiment of the present disclosure.
  • the steps shown in FIG. 2 may be performed by computing device 100 .
  • the steps in FIG. 2 may be implemented by a plurality of entities, such that some of the steps shown in FIG. 2 are performed in a user terminal and others are performed in a server.
  • the computing device 100 may obtain a result of performing nucleotide sequence analysis on DNA or RNA obtained from a biological sample derived from a subject (210).
  • the computing device 100 may obtain a result of performing nucleotide sequence analysis (eg, NGS) from a server or an external entity. In another embodiment, the computing device 100 may perform nucleotide sequence analysis on genetic data (eg, DNA or RNA) obtained from a biological sample derived from a subject.
  • NGS nucleotide sequence analysis
  • the computing device 100 may perform nucleotide sequence analysis on genetic data (eg, DNA or RNA) obtained from a biological sample derived from a subject.
  • the computing device 100 may determine the HLA type of the biological sample based on the HLA type candidates included in the calls obtained from the plurality of HLA typing tools and the complementary score between the plurality of HLA typing tools (220).
  • the computing device 100 may use three or more tools selected from among a plurality of HLA typing tools to determine the HLA type from the result of sequencing. For example, the computing device may determine the final HLA type from the HLA type (or HLA type candidates) obtained from a combination of three or four selected from among OptiType, HLA-HD, PHLAT, HLAscan, and HLA*LA.
  • the names of the aforementioned HLA typing tools are used for illustrative purposes for convenience of explanation, and additional HLA typing tools may be used or only some of the aforementioned HLA typing tools may be used according to implementation aspects.
  • a call from an HLA typing tool may mean an HLA typing result output from the HLA typing tool.
  • HLA type candidates output from each of a plurality of HLA typing tools may correspond to calls from the HLA typing tool.
  • HLA typing with high accuracy and/or usability can be achieved by combining results of a plurality of tools through a novel algorithm.
  • HLA Human Leukocyte Antigen
  • NGS next-generation sequencing
  • the inventors of the present disclosure have confirmed that the accuracy of HLA Class I typing is significantly improved when all or at least some of a plurality of HLA typing tools are used and when a mutual complement score between a plurality of HLA typing tools is used, in particular, the present disclosure It was found that the embodiments of are the optimal HLA type determination method with improved reliability. Therefore, when using the HLA type determination method according to an embodiment of the present invention, it is expected that personalization of medical care, such as determining whether to additionally perform PCR-SBT as well as histocompatibility testing to increase the transplant success rate, is expected.
  • the computing device 100 may determine the number of tools that presented calls among a plurality of HLA typing tools and determine the HLA type based on the determined number of tools.
  • Each HLA typing tool may output a call including an HLA typing result through its own unique algorithm. For example, if there are a total of 5 tools presenting calls, and all HLA types included in the calls presented by the 5 tools match or all 4 tools match, the matching HLA type is selected as the final HLA type.
  • the computing device 100 determines the number of tools that present calls from among a plurality of HLA typing tools, determines the degree of agreement between HLA type candidates included in the presented calls, and based on the determined number of tools and the determined degree of agreement , It is possible to determine the HLA type.
  • the number of tools presenting a call is too small (eg, only two tools present a call) and/or there are two HLA type candidates among the HLA type candidates included in the call, a plurality of It may be determined that the reliability of the HLA type candidate obtained from the tools is low.
  • the reliability of the finally determined HLA type is high.
  • the determined HLA type may be determined and output as the final HLA type.
  • the degree of coincidence may indicate the number of calls in which the HLA type included in the call presented by the tool performing HLA typing matches.
  • OptiType, HLA-HD, PHLAT, HLAscan, and HLA*LA all presented calls, and if the HLA types included in three of these calls are the same, the degree of concordance can be expressed as 3/5, If the HLA types included in four of these calls are the same, the degree of concordance may be expressed as 4/5.
  • the expression method and calculation method for the degree of concordance are not limited to the above examples, and any form of method indicating the identity of the HLA type included in the call may be included within the scope of the degree of concordance as long as it does not depart from the scope of the present disclosure. .
  • a computing device determines the number of available calls among calls presented by a plurality of tools, and based on the number of available calls, generates a matching criterion for determining the HLA type. And, based on the generated matching criterion, the HLA type may be determined.
  • the match criterion may indicate a match threshold for determining the HLA type.
  • the usable call may mean a call usable for determining an HLA type among calls presented by the HLA typing tool.
  • available calls may mean all calls presented by a plurality of HLA typing tools. In this example, calls presented by the remaining tools, except for the tool that did not present the call, may be considered usable calls.
  • the consistency criterion may vary according to the number of available calls. As another example, the consistency criterion may vary depending on the number of available calls and HLA type candidates included in the calls.
  • the computing device 100 determines, when a specific type is presented only in five methods among a plurality of HLA typing tools, an HLA type candidate identically presented in all five methods as the final HLA type.
  • the HLA type candidate presented identically in three or four methods may be determined as the final HLA type, but the scope of the present disclosure is not limited thereto.
  • the computing device 100 during the process of analyzing the HLA type, when multiple calls are presented by one or more tools among a plurality of HLA typing tools, the HLA typing tool presenting the multiple calls
  • the result from may be determined to be excluded in determining the final HLA type. That is, the computing device 100 may determine that it is not usable for multiple calls in this case, but is not limited thereto.
  • the computing device 100 calculates a complementary score between any two typing tools among a plurality of HLA typing tools in determining the HLA type, and based on the complementary score, the biological The HLA type for the sample can be determined.
  • the complementarity score may include a value quantitatively indicating the possibility that any two HLA typing tools among a plurality of HLA typing tools can be used together to determine the HLA type.
  • a complementary score may be generated corresponding to a combination of two HLA typing tools. For example, assuming that there are four HLA typing tools including A, B, C, and D, A and B, A and C, A and D, B and A, B and C, and B and D , C and A, C and B, C and D, D and A, D and B, and D and C, the number of complementary scores corresponding to each other may be generated. In another example, assuming that there are four HLA typing tools including A, B, C, and D, A and B, A and C, A and D, B and C, B and D, and C and A number of complementary scores corresponding to D may be generated.
  • the mutual complementation score may indicate the possibility of complementation when one of the two HLA typing tools is used together, compared to when either one of the two HLA typing tools is used.
  • the complementary score may represent a score for a combination of three or more HLA typing tools rather than two.
  • the complementary score may include a value quantitatively indicating the accuracy of the determined HLA type when any two HLA typing tools among a plurality of HLA typing tools are used together. For example, it is assumed that the accuracy of the comparison result between the HLA typing result in one HLA typing tool and the actual HLA type is 70%. Under this assumption, if the accuracy of the final HLA typing result determined by referring to the results output from the one HLA typing tool and the other HLA typing tool, which is different from the one HLA typing tool, is 85%, the mutual complement between these two HLA typing tools The score may be set to have a relatively high value. Conversely, when the accuracy is not higher than that of one HLA typing tool even when two HLA typing tools are combined, a relatively low complementary score may be set.
  • the complementary score is a quantitative correction value to be applied to HLA type candidates included in calls obtained from a plurality of HLA typing tools when any two HLA typing tools are used together. It may contain a value represented by .
  • a first accuracy numerical value for the first HLA typing tool is combined with a second HLA typing tool for the first HLA typing tool.
  • a first complementary scoring value may be added as a correction value.
  • the first HLA typing tool when used in conjunction with the second HLA typing tool, generates an accuracy value obtained by adding a first accuracy numerical value inherent in the first HLA typing tool and a correction value corresponding to the first complementary scoring.
  • the second HLA typing tool when used together, according to the combination of the first HLA typing tool with respect to the second HLA typing tool to the second accuracy numerical value for the second HLA typing tool.
  • a second complementary scoring value may be added as a correction value.
  • the second HLA typing tool when used in conjunction with the first HLA typing tool, generates an accuracy value that is the sum of a second accuracy numerical value inherent in the second HLA typing tool and a correction value corresponding to the second complementary scoring.
  • a complementary score between a first HLA typing tool and a second HLA typing tool among a plurality of HLA typing tools is a result of a first call obtained from the first HLA typing tool for a biological sample.
  • a complementary score between a first HLA typing tool and a second HLA typing tool among a plurality of HLA typing tools is obtained when the first HLA typing tool is used together with the second HLA typing tool.
  • the determined accuracy value for the HLA type may include a value quantitatively indicating a result of comparison with a predetermined first accuracy value for the first HLA typing tool. For example, a difference between a first accuracy value inherent in the first HLA typing tool and an accuracy value when the first HLA typing tool and the second HLA typing tool are used together may represent a complementary score.
  • the computing device 100 may determine whether to combine a plurality of HLA typing tools based on the value of the complementarity score. For example, the computing device 100 determines whether to combine a first call obtained from a first HLA typing tool and a second call obtained from a second HLA typing tool among a plurality of HLA typing tools. based on a first complementary score between the tool and the second HLA typing tool. Determining whether or not to combine such a combination may be performed according to a comparison between a predetermined threshold and a mutual complement score.
  • the computing device 100 may determine to combine the two HLA typing tools.
  • the first HLA typing tool and the second HLA typing tool are combined, the accuracy inherent in the first HLA typing tool or the accuracy inherent in the second HLA typing tool is determined through the complementary score. In this case, the computing device 100 may determine to combine the two HLA typing tools.
  • the computing device 100 determines whether to combine a first call obtained from a first HLA typing tool and a second call obtained from a second HLA typing tool among a plurality of HLA typing tools, the based on a first complementarity score between a first HLA typing tool and a second HLA typing tool, a first predetermined accuracy value for the first HLA typing tool and a second predetermined accuracy value for the second HLA typing tool can be determined by For example, a complementary score when a first HLA typing tool is combined with a second HLA typing tool together with a first accuracy value inherent in the first HLA typing tool and a second accuracy value inherent in the second HLA typing tool. Using as factors, the computing device 100 may determine whether to output an HLA typing result by combining the first HLA typing tool and the second HLA typing tool.
  • the computing device 100 determines a correction value to be applied to a first call obtained from a first HLA typing tool and a second call obtained from a second HLA typing tool among the plurality of HLA typing tools. It may be determined based on a first complementary score between the first HLA typing tool and the second HLA typing tool.
  • the computing device 100 may determine the HLA type corresponding to the biological sample based on the correction value. For example, when calls obtained from two HLA typing tools match each other, and when the complementary score between the two tools has a relatively high value (eg, when it has a value greater than or equal to a predetermined threshold value), computing The device 100 may determine the final HLA type as the HLA type corresponding to the two matching calls. In this example, the computing device 100 may consider calls from HLA typing tools other than the two HLA typing tools together with their complementary scores to determine which tool results to use as the HLA typing result. there is.
  • the computing device 100 may determine a degree of similarity between algorithms included in a plurality of HLA typing tools based on the complementary score.
  • the complementary score of the second HLA typing tool with respect to the first HLA typing tool may be used as an index indicating the possibility that the result of the second HLA typing tool is correct when the result of the first HLA typing tool is incorrect. This can also be used as an index indicating a difference between the typing algorithm of the first HLA typing tool and the algorithm of the second HLA typing tool.
  • the computing device 100 may calculate similarities or differences between typing methods or typing algorithms for each HLA typing tool based on the calculated complementarity score.
  • FIG. 3 illustrates an example algorithm for determining a complementarity score, according to one embodiment of the present disclosure.
  • HLA typing tools described in FIGS. 3-5 are used for illustrative purposes, and depending on the implementation, additional HLA typing tools or only some of them may be used.
  • additional HLA typing tools may include any type of tools for HLA typing, such as Polysolver, HLAreporter, HLAforest, and HLAminer.
  • Opt represents OptiType
  • HD represents HLA-HD (HLA typing from High-quality Dictionary)
  • Phlat, SeqLA, and kourami are PHLAT and seq2HLA, respectively, by themselves.
  • arcas denotes arcasHLA
  • Scan denotes HLAscan
  • *LA was used to denote HLA*LA.
  • FIG. 3 shows an exemplary data structure for expressing a correction score, which is one of factors for determining a complementary score.
  • the data structure 300 shown by reference numeral 300 in FIG. 3 shows the result of the maintype HLA typing tool when each of the subtype HLA typing tools is combined for each of the maintype HLA typing tools among eight HLA typing tools. Indicates the score that the subtype's HLA typing tool can correct.
  • the data structure 300 is a result obtained by combining a plurality of HLA typing tools for a large amount of samples.
  • the correction score of the second HLA typing tool of a specific subtype for the first HLA typing tool of a specific maintype is, in an experiment targeting a large number of samples, the first HLA typing tool It may be determined based on information on the number of times the result for is wrong and information on the number of times the result for the second HLA typing tool is correct when the result for the first HLA typing tool is wrong.
  • the correction score may have a higher value as a value for the number of times that the result of the second HLA typing tool is correct when the result of the first HLA typing tool is incorrect. As such, the correction score quantitatively indicates the possibility of correcting the result of using a specific HLA typing tool through another HLA typing tool.
  • the value of the correction score shown in FIG. 3 increases, it indicates that the HLA typing tool of the subtype is more likely to correct the HLA typing tool of the maintype. As the value of the correction score increases, the value of the mutual complementation score may increase.
  • the value of the correction score may be included in the range of 0 to 1. In this example, the closer the value of the correction score is to 1, the higher the possibility that the subtype corrects the result of the maintype and outputs an accurate value.
  • FIG. 4 illustrates an exemplary algorithm for determining a complementarity score, according to one embodiment of the present disclosure.
  • FIG. 4 shows an exemplary data structure for expressing a complementary ratio, which is one of the factors for determining a complementary score.
  • FIG. 5 may include a table of complementarity ratios for a plurality of HLA typing tools.
  • the complementarity ratio of HLA typing tool B to HLA typing tool A may be determined based on the correction score of B to A and the accuracy value inherent in B.
  • the complementarity ratio of an HLA typing tool B to an HLA typing tool A is 1 minus B's accuracy value as the denominator and 1 minus B's correction score for A as the numerator. can be determined by
  • the accuracy value may be included in the range of 0 to 1.
  • the complementarity ratio of HLA typing tool B to HLA typing tool A may be determined based on the correction score of B to A and the implicit accuracy value of A.
  • the complementarity ratio of an HLA typing tool B to an HLA typing tool A is 1 minus A's accuracy value as the denominator and 1 minus B's correction score for A as the numerator. can be determined by
  • two complementarity ratios may be calculated for two HLA type tools.
  • the complementarity ratio of B to A and the complementarity ratio of A to B can be calculated.
  • two complementary ratios may be calculated according to the relationship between maintype and subtype for two corresponding HLA typing tools.
  • the higher the value of the complementarity ratio the higher the probability of correcting the result for the maintype compared to the accuracy of the HLA typing result inherent in the subtype.
  • the higher the value of the complementarity ratio the higher the accuracy corresponding to the corrected result according to the result from the subtype compared to the HLA typing accuracy inherent in the maintype.
  • the value of the complementarity ratio greater than 1 may mean that the accuracy inherent in the corresponding HLA typing tool is outperformed when combined with.
  • FIG. 5 depicts an exemplary algorithm for determining a complementarity score according to one embodiment of the present disclosure.
  • FIG. 5 illustrates an example data structure for representing a complementary score.
  • FIG. 5 may include a table of complementary scores for a plurality of HLA typing tools.
  • the computing device 100 may use the complementary score shown in FIG. 5 to determine whether to combine the results of a plurality of HLA typing tools. Additionally, in order to predict the accuracy of an HLA typing result when a plurality of HLA typing tools are combined according to an embodiment of the present disclosure, the computing device 100 may use the complementary score shown in FIG. 5 .
  • computing device 100 may use a complementarity score to determine similarity of HLA typing algorithms among a plurality of HLA typing tools. For example, it indicates that a plurality of HLA typing tools having a relatively high value of complementarity score are highly likely to have different algorithms. In addition, a plurality of HLA typing tools having a relatively small complementarity score indicate that the algorithms between them are highly likely to be the same or similar.
  • the complementary score is determined by determining whether a first result from a first HLA typing tool among a plurality of HLA typing tools does not match an actual result, and a second result from a second HLA typing tool being the actual result.
  • a first sub-score indicating a case in which the result matches the actual result, and a first result from the first HLA typing tool in case the second result from the second HLA typing tool among the plurality of HLA typing tools does not match the actual result. It may be calculated based on the second sub-score indicating the case of coincidence, the first accuracy value predetermined for the first HLA typing tool, and the second accuracy value predetermined for the second HLA typing tool.
  • the first sub-score includes a complementarity ratio or correction score of the second HLA typing tool to the first HLA typing tool
  • the second sub-score includes the complementary score of the first HLA typing tool to the second HLA typing tool. It can include ratios or correction scores.
  • a value of one complementary score may be calculated for two corresponding HLA typing tools.
  • the complementarity scores of HLA typing tool A and HLA typing tool B are the complementarity ratio of HLA typing tool B to HLA typing tool A and HLA typing tool A to HLA typing tool B. It can be determined based on the mutual complement ratio of
  • the complementary score of A and B may be determined based on the sum of the complementary ratio of B to A and the complementary ratio of A to B.
  • the complementarity score of A and B may mean the average of the complementarity ratio of B to A and the complementarity of A to B.
  • HLA typing tool A HLA typing tool A
  • HLA typing tool B HLA typing tool B
  • HLA typing tool C HLA typing tool D
  • HLA typing tool D HLA typing tool D
  • a unique accuracy value is mapped to each of these four HLA typing tools.
  • combinations for a total of five HLA typing tools including AB, AC, AD, BC, and CD may be determined.
  • a predetermined complementary score may be assigned to each of these five combinations. That is, a total of five complementary scores may be determined for the five combinations.
  • the computing device 100 obtains data obtained from the four HLA typing tools based on the accuracy values assigned to each of the four HLA typing tools and the complementarity score assigned to each of the five combinations of the HLA typing tools. It is possible to determine which of the results from the calls made is selected as the final HLA typing result. Alternatively, a total of 5 mutually complementary scores may be determined.
  • the computing device 100 obtains data obtained from the four HLA typing tools based on the accuracy values assigned to each of the four HLA typing tools and the complementarity score assigned to each of the five combinations of the HLA typing tools. You can decide whether and/or what to do with the combined calls.
  • the complementarity score assigned to each of the five combinations of HLA typing tools can be obtained from the exemplary table shown in FIG. 5 .
  • the computing device 100 includes a first factor including accuracy values assigned to each of A, B, C, and D, and an average of complementary scores assigned to each of AB, AC, AD, BC, and CD. Based on the second factor, it is possible to determine whether to select the results of the calls obtained from the four HLA typing tools as the final HLA typing result.
  • the computing device 100 calculates a first factor including accuracy values assigned to A, B, C, and D, respectively, and an average and a total of complementary scores assigned to each of AB, AC, AD, BC, and CD. Based on the second factor obtained by calculating K (for example, 4), the number of HLA typing tools, it may be determined whether to select the results of calls obtained from the four HLA typing tools as the final HLA typing result.
  • K for example, 4
  • the computing device 100 divides the total sum of the complementarity scores assigned to each of AB, AC, AD, BC, and CD by the number of combinations K times, which is the total number of HLA typing tools (eg, , 4) and the first factor including the accuracy values assigned to A, B, C, and D, respectively, the results in the calls obtained from the four HLA typing tools are finalized. You can decide whether to select based on the HLA typing result.
  • Equation 1 above shows an exemplary calculation formula for determining whether to combine results of a plurality of HLA typing tools according to an embodiment of the present disclosure. Additionally, Equation 1 may be used as an exemplary calculation formula for determining the accuracy of an HLA typing result when a plurality of HLA typing tools are combined according to an embodiment of the present disclosure. Equation 1 is used for illustrative purposes, and various types of equations or calculation algorithms using the accuracy information of each of the plurality of HLA typing tools and the mutual complement scores between the plurality of HLA typing tools as factors according to implementation aspects can be used
  • Equation 1 k represents the number of HLA typing tools used, n represents the number of combinations between HLA typing tools, Acc represents an accuracy value assigned to each of the HLA typing tools, and Value cor represents HLA typing Indicates a complementary score corresponding to a combination of tools.
  • Equation 1 described above can be used to calculate a final accuracy value for a combination of HLA typing tools used to determine an HLA type, using accuracy information of each of the HLA typing tools and complementary score information of a combination of the HLA typing tools.
  • the computing device 100 compares the final accuracy value according to Equation 1 and a predetermined threshold value (eg, a value such as 99.8%) to determine whether to combine a plurality of HLA typing tools and / or Reliability of HLA typing results obtained from a plurality of HLA typing tools may be determined.
  • a predetermined threshold value eg, a value such as 99.8%
  • the computing device 100 may determine whether to combine calls obtained from a plurality of HLA typing tools based on the algorithm according to Equation 1 described above. As another example, the computing device 100 may determine a final HLA type result by determining weights for calls obtained from a plurality of HLA typing tools based on the algorithm according to Equation 1 described above.
  • the computing device 100 determines an HLA type candidate to be determined as the final HLA type among HLA type candidate values included in calls obtained from a plurality of HLA typing tools based on the algorithm according to Equation 1 described above. can decide
  • the HLA typing method uses a plurality of HLA typing tools, but obtains a higher score from calls obtained from a plurality of HLA typing tools based on a complementary score between the plurality of HLA typing tools. Accurate HLA typing results can be obtained.
  • the value of the complementarity score greater than 1 may mean that it outperforms its inherent accuracy when combined with.
  • the computing device 100 extracts DNA or RNA from a biological sample derived from a subject and uses PCR-SBT (Polymerase Chain Reaction -Sequencing Based Typing) may be performed.
  • the computing device may obtain a corresponding result by acquiring an execution result of PCR-SBT executed by another entity.
  • the degree of concordance of the HLA type included in the call is low or the degree of certainty of the HLA typing result is high even considering the mutual complement score. It may correspond to a situation below the determined threshold. In this case, it may mean that the accuracy of HLA typing output by the corresponding algorithm is reduced. In this case, it may be desirable to increase the accuracy of HLA type determination by performing additional PCR-SBT.
  • PCR-SBT can be used as an auxiliary test in situations where additional HLA genotype information is required or the determination of PCR-SSP test results is ambiguous.
  • a disadvantage of PCR-SSO or RFLP is that it can detect single-base differences in the DNA sequence between two alleles, but it is less likely to detect a new, undefined allele unless the mutation occurs at a specific site detected by the probe. It is.
  • PCR-SBT was originally developed as a manual sequencing method, and the introduction of dye-labeled primers and fluorescence automated sequencing enabled automation and greatly improved accuracy.
  • PCR-SBT is a technology that directly detects the nucleotide sequence of an allele, and has excellent accuracy, but it takes a long time, is expensive, and has a low sample throughput.
  • PCR may be real-time PCR, and more specifically may be single PCR or multiplex PCR, but is not limited thereto.
  • the single or multiplex real-time PCR reaction conditions may take conventional conditions.
  • single real-time PCR and multiplex real-time PCR reactions can be performed under the same conditions. For example, initial denaturation is performed at 95 ° C for 1 minute, followed by denaturation (95 ° C for 25 seconds), annealing (annealing, 45 seconds at 65 ° C.) and extension (extension, 30 seconds at 72 ° C.) may be performed a total of 40 times.
  • Real-time PCR devices usable in the present disclosure include Real-time PCR devices 7900, 7500, and 7300 from AB, LightCycler 80 from Roche, Mx3000p from Stratagene, and Chromo 4 devices from BioRad, which are described for illustrative purposes. However, the scope of the present disclosure is not limited to specific descriptions of the characteristics of the PCR device and the PCR reaction.
  • the PCR may be PCR-SSOP (PCR sequence-specific oligonucleotide probes) or PCR-SBT (PCR sequencing-based typing), but is not limited thereto.
  • FIG. 6 is a schematic diagram of a computing environment according to one embodiment of the present disclosure.
  • a component, module or unit in this disclosure includes routines, procedures, programs, components, data structures, etc. that perform particular tasks or implement particular abstract data types.
  • routines, procedures, programs, components, data structures, etc. that perform particular tasks or implement particular abstract data types.
  • methods presented in this disclosure can be used in single-processor or multiprocessor computing devices, minicomputers, mainframe computers as well as personal computers, handheld computing devices, microprocessor-based or programmable consumer electronics, and the like ( It will be fully appreciated that each of these may be implemented with other computer system configurations, including those that may be operative in connection with one or more associated devices.
  • Embodiments described in this disclosure may also be practiced in distributed computing environments where certain tasks are performed by remote processing devices that are linked through a communications network.
  • program modules may be located in both local and remote memory storage devices.
  • a computing device typically includes a variety of computer readable media.
  • Computer readable media can be any medium that can be accessed by a computer, including volatile and nonvolatile media, transitory and non-transitory media, removable and non-transitory media. Includes removable media.
  • Computer readable media may include computer readable storage media and computer readable transmission media.
  • Computer readable storage media are volatile and nonvolatile media, transitory and non-transitory, removable and non-removable media implemented in any method or technology for storage of information such as computer readable instructions, data structures, program modules or other data. includes media
  • Computer readable storage media may include RAM, ROM, EEPROM, flash memory or other memory technology, CD-ROM, digital video disk (DVD) or other optical disk storage device, magnetic cassette, magnetic tape, magnetic disk storage device or other magnetic storage device. device, or any other medium that can be accessed by a computer and used to store desired information.
  • a computer readable transmission medium typically embodies computer readable instructions, data structures, program modules or other data in a modulated data signal such as a carrier wave or other transport mechanism. Including all information delivery media.
  • modulated data signal means a signal that has one or more of its characteristics set or changed so as to encode information within the signal.
  • computer readable transmission media includes wired media such as a wired network or direct-wired connection, and wireless media such as acoustic, RF, infrared, and other wireless media. Combinations of any of the above are also intended to be included within the scope of computer readable transmission media.
  • An exemplary environment 2000 implementing various aspects of the present invention is shown comprising a computer 2002, which includes a processing unit 2004, a system memory 2006 and a system bus 2008. do.
  • Computer 200 herein may be used interchangeably with a computing device.
  • System bus 2008 couples system components, including but not limited to system memory 2006, to processing unit 2004.
  • Processing unit 2004 may be any of a variety of commercially available processors. Dual processors and other multiprocessor architectures may also be used as the processing unit 2004.
  • System bus 2008 may be any of several types of bus structures that may additionally be interconnected to a memory bus, a peripheral bus, and a local bus using any of a variety of commercial bus architectures.
  • System memory 2006 includes read only memory (ROM) 2010 and random access memory (RAM) 2012 .
  • the basic input/output system (BIOS) is stored in non-volatile memory 2010, such as ROM, EPROM, EEPROM, etc. BIOS is a basic set of information that helps transfer information between components within the computer 2002, such as during startup. contains routines.
  • RAM 2012 may also include high-speed RAM, such as static RAM, for caching data.
  • the computer 2002 may also read from an internal hard disk drive (HDD) 2014 (eg EIDE, SATA), a magnetic floppy disk drive (FDD) 2016 (eg a removable diskette 2018), or for writing to them), SSDs and optical disk drives 2020 (for example, for reading CD-ROM disks 2022 or reading from or writing to other high capacity optical media such as DVDs) include
  • HDD hard disk drive
  • FDD magnetic floppy disk drive
  • optical disk drives 2020 for example, for reading CD-ROM disks 2022 or reading from or writing to other high capacity optical media such as DVDs
  • the hard disk drive 2014, magnetic disk drive 2016, and optical disk drive 2020 are connected to the system bus 2008 by the hard disk drive interface 2024, magnetic disk drive interface 2026, and optical drive interface 2028, respectively.
  • the interface 2024 for external drive implementation includes, for example, at least one or both of Universal Serial Bus (USB) and IEEE 1394 interface technologies.
  • USB Universal Serial Bus
  • drives and their associated computer readable media provide non-volatile storage of data, data structures, computer executable instructions, and the like.
  • drives and media correspond to storing any data in a suitable digital format.
  • computer-readable storage media refers to HDDs, removable magnetic disks, and removable optical media such as CDs or DVDs, those skilled in the art can use zip drives, magnetic cassettes, flash memory cards, cartridges, It will be appreciated that other types of computer-readable storage media, such as those of other types, may also be used in the exemplary operating environment and that any such media may contain computer-executable instructions for performing the methods of the present invention. .
  • a number of program modules may be stored on the drive and RAM 2012, including an operating system 2030, one or more application programs 2032, other program modules 2034, and program data 2036. All or portions of the operating system, applications, modules and/or data may also be cached in RAM 2012. It will be appreciated that the present invention may be implemented in a variety of commercially available operating systems or combinations of operating systems.
  • a user may enter commands and information into the computer 2002 through one or more wired/wireless input devices, such as a keyboard 2038 and a pointing device such as a mouse 2040.
  • Other input devices may include a microphone, IR remote control, joystick, game pad, stylus pen, touch screen, and the like.
  • an input device interface 2042 that is connected to the system bus 2008, a parallel port, IEEE 1394 serial port, game port, USB port, IR interface, may be connected by other interfaces such as the like.
  • a monitor 2044 or other type of display device is also connected to the system bus 2008 through an interface such as a video adapter 2046.
  • computers typically include other peripheral output devices (not shown) such as speakers, printers, and the like.
  • Computer 2002 may operate in a networked environment using logical connections to one or more remote computers, such as remote computer(s) 2048 via wired and/or wireless communications.
  • Remote computer(s) 2048 may be workstations, server computers, routers, personal computers, handheld computers, microprocessor-based entertainment devices, peer devices, or other common network nodes, and generally relate to computer 2002.
  • the logical connections shown include wired/wireless connections to a local area network (LAN) 2052 and/or a larger network, such as a wide area network (WAN) 2054 .
  • LAN and WAN networking environments are common in offices and corporations and facilitate enterprise-wide computer networks, such as intranets, all of which can be connected to worldwide computer networks, such as the Internet.
  • computer 2002 When used in a LAN networking environment, computer 2002 is connected to local network 2052 through wired and/or wireless communication network interfaces or adapters 2056. Adapter 2056 may facilitate wired or wireless communications to LAN 2052, which also includes a wireless access point installed therein to communicate with wireless adapter 2056.
  • computer 2002 When used in a WAN networking environment, computer 2002 may include a modem 2058, be connected to a communications server on WAN 2054, or other means of establishing communications over WAN 2054, such as over the Internet. have Modem 2058, which can be internal or external and wired or wireless, is connected to system bus 2008 through serial port interface 2042.
  • program modules described for computer 2002, or portions thereof may be stored in remote memory/storage device 2050. It will be appreciated that the network connections shown are exemplary and other means of establishing a communication link between computers may be used.
  • Computer 1602 is any wireless device or entity that is deployed and operating in wireless communication, such as printers, scanners, desktop and/or portable computers, portable data assistants (PDAs), communication satellites, and associated with wireless detectable tags. It operates to communicate with arbitrary equipment or places and telephones. This includes at least Wi-Fi and Bluetooth wireless technologies. Thus, the communication may be a predefined structure as in conventional networks or simply an ad hoc communication between at least two devices.
  • wireless communication such as printers, scanners, desktop and/or portable computers, portable data assistants (PDAs), communication satellites, and associated with wireless detectable tags. It operates to communicate with arbitrary equipment or places and telephones. This includes at least Wi-Fi and Bluetooth wireless technologies. Thus, the communication may be a predefined structure as in conventional networks or simply an ad hoc communication between at least two devices.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé de typage d'un antigène leucocytaire humain (HLA), effectué par un dispositif informatique. Le procédé peut comprendre les étapes suivantes : obtention d'un résultat d'analyse de séquence nucléotidique sur l'ADN ou l'ARN obtenu à partir d'un échantillon biologique prélevé sur le sujet ; et typage d'un HLA pour l'échantillon biologique en utilisant les résultats et un score mutuellement complémentaire d'une pluralité d'outils de typage HLA en utilisant le résultat d'analyse de séquence nucléotidique comme intrant. Un dessin représentatif peut être représenté par la figure 2.
PCT/KR2022/020521 2022-01-11 2022-12-16 Procédé et dispositif de typage d'antigène leucocytaire humain WO2023136486A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020220004045A KR102547350B1 (ko) 2022-01-11 2022-01-11 인간 백혈구 항원의 타입을 결정하기 위한 방법 및 장치
KR10-2022-0004045 2022-01-11

Publications (1)

Publication Number Publication Date
WO2023136486A1 true WO2023136486A1 (fr) 2023-07-20

Family

ID=86993450

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2022/020521 WO2023136486A1 (fr) 2022-01-11 2022-12-16 Procédé et dispositif de typage d'antigène leucocytaire humain

Country Status (2)

Country Link
KR (2) KR102547350B1 (fr)
WO (1) WO2023136486A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111105843A (zh) * 2019-12-31 2020-05-05 杭州纽安津生物科技有限公司 一种hla i型分子与多肽的亲和力预测方法
KR20210110241A (ko) * 2020-02-28 2021-09-07 (주)신테카바이오 인간백혈구항원 하플로타입 기반 다중 분류 인공지능 모델을 이용한 면역항암제 적응증 및 반응 예측 시스템 및 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2972366B1 (fr) 2013-03-15 2020-06-17 Prognosys Biosciences, Inc. Procédés de détection de liaison peptide/mhc/tcr

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111105843A (zh) * 2019-12-31 2020-05-05 杭州纽安津生物科技有限公司 一种hla i型分子与多肽的亲和力预测方法
KR20210110241A (ko) * 2020-02-28 2021-09-07 (주)신테카바이오 인간백혈구항원 하플로타입 기반 다중 분류 인공지능 모델을 이용한 면역항암제 적응증 및 반응 예측 시스템 및 방법

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANTTI LARJO, ROBERT EVELEIGH, ELINA KILPELäINEN, TONY KWAN, TOMI PASTINEN, SATU KOSKELA, JUKKA PARTANEN: "Accuracy of Programs for the Determination of Human Leukocyte Antigen Alleles from Next-Generation Sequencing Data", FRONTIERS IN IMMUNOLOGY, vol. 8, XP055737144, DOI: 10.3389/fimmu.2017.01815 *
DOUILLARD VENCESLAS, CASTELLI ERICK C., MACK STEVEN J., HOLLENBACH JILL A., GOURRAUD PIERRE-ANTOINE, VINCE NICOLAS, LIMOU SOPHIE: "Approaching Genetics Through the MHC Lens: Tools and Methods for HLA Research", FRONTIERS IN GENETICS, vol. 12, XP093081329, DOI: 10.3389/fgene.2021.774916 *
LEE MISEON, SEO JEONG-HAN, SONG SUNGJAE, SONG IN HYE, KIM SU YEON, KIM YOUNG-AE, GONG GYUNGYUB, KIM JEONG EUN, LEE HEE JIN: "A New Human Leukocyte Antigen Typing Algorithm Combined With Currently Available Genotyping Tools Based on Next-Generation Sequencing Data and Guidelines to Select the Most Likely Human Leukocyte Antigen Genotype", FRONTIERS IN IMMUNOLOGY, vol. 12, XP093081333, DOI: 10.3389/fimmu.2021.688183 *

Also Published As

Publication number Publication date
KR102547350B1 (ko) 2023-06-23
KR20230108723A (ko) 2023-07-18

Similar Documents

Publication Publication Date Title
Heather et al. High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities
Ka et al. HLAscan: genotyping of the HLA region using next-generation sequencing data
Norman et al. Sequences of 95 human MHC haplotypes reveal extreme coding variation in genes other than highly polymorphic HLA class I and II
Gutierrez-Arcelus et al. Autoimmune diseases—connecting risk alleles with molecular traits of the immune system
Crysnanto et al. Novel functional sequences uncovered through a bovine multiassembly graph
Natri et al. Genome-wide DNA methylation and gene expression patterns reflect genetic ancestry and environmental differences across the Indonesian archipelago
Hassan et al. De novo reconstruction of the Toxoplasma gondii transcriptome improves on the current genome annotation and reveals alternatively spliced transcripts and putative long non-coding RNAs
Thielen et al. Genomic diversity of SARS-CoV-2 during early introduction into the Baltimore–Washington metropolitan area
WO2019139363A1 (fr) Procédé de détection d'adn tumoral circulant dans un échantillon comprenant de l'adn acellulaire et son utilisation
JP2018500625A (ja) シーケンシングリードのｄｅ ｎｏｖｏアセンブリーの方法、システム、およびプロセス
Chen et al. In silico tools for accurate HLA and KIR inference from clinical sequencing data empower immunogenetics on individual-patient and population scales
SoRelle et al. Assembling and validating bioinformatic pipelines for next-generation sequencing clinical assays
WO2024101698A1 (fr) Procédé et appareil pour établir un rapport de récepteur de lymphocytes t pour une efficacité optimale d'une thérapie par lymphocytes t d'expression de récepteur de lymphocytes t
Farahani et al. Frequency of HLA Alleles in a Group of Severe COVID-19 Iranian patients
EP3977460A1 (fr) Procédés d'identification et d'utilisation d'antigènes associés à une maladie
Ritari et al. Computational analysis of HLA-presentation of Non-synonymous recipient mismatches indicates effect on the risk of chronic graft-vs.-host disease after allogeneic HSCT
Dezordi et al. on behalf of the Fiocruz COVID-19 Genomic Surveillance Network
Grace et al. Candidates for balancing selection in Leishmania donovani complex parasites
WO2023136486A1 (fr) Procédé et dispositif de typage d'antigène leucocytaire humain
Bossini-Castillo et al. Immune disease variants modulate gene expression in regulatory CD4+ T cells and inform drug targets
US10540324B2 (en) Human haplotyping system and method
WO2020235721A1 (fr) Procédé de découverte de marqueur permettant de prédire le risque de dépression ou de suicide à l'aide d'une analyse multi-omique, marqueur permettant de prédire le risque de dépression ou de suicide, et procédé permettant de prédire le risque de dépression ou de suicide à l'aide d'une analyse multi-omique
WO2022108407A1 (fr) Procédé de diagnostic du cancer et de prédiction de pronostic utilisant un rapport de longueur d'acides nucléiques
Probst et al. A new Trypanosoma cruzi genotyping method enables high resolution evolutionary analyses
Hullegie-Peelen et al. Virus-specific TRM cells of both donor and recipient origin reside in human kidney transplants

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22920815

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE